Uncategorized

How cost and perception could reshape the GLP-1 market

As Eli Lilly and Novo Nordisk race for share, surveys show affordability and prescribing preferences may help decide the winners.

Published

4 weeks ago

on

August 21, 2026

By

Temp User

As Eli Lilly and Novo Nordisk race for share, surveys show affordability and prescribing preferences may help decide the winners.

Related Topics:

Leave a Reply

Fierce Biotech6 months ago

Scientists turn pig semen extract into eye drops that kill cancer in mice
Endpoints News6 months ago

Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Uncategorized6 months ago

Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Nature Biotechnology6 months ago

Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
Uncategorized4 months ago

Optical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
Uncategorized4 months ago

Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study

Exit mobile version